Ensign Peak Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Ensign Peak Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.9M	Sell	7,116 -6,446	-48%	-$1.51M	﹤0.01%	753
2026 Q1	$3.1M	Sell	13,562 -55,998	-81%	-$12.6M	0.01%	627
2025 Q4	$14.8M	Sell	69,560 -1,164	-2%	-$240K	0.03%	333
2025 Q3	$14.1M	Buy	70,724 +9,000	+15%	+$1.68M	0.02%	382
2025 Q2	$10.7M	Hold	61,724	–	–	0.02%	453
2025 Q1	$9.62M	Buy	61,724 +59,501	+2,677%	+$8.5M	0.02%	475
2024 Q4	$306K	Sell	2,223 -760	-25%	-$99.9K	﹤0.01%	1673
2024 Q3	$445K	Sell	2,983 -108	-3%	-$14.6K	﹤0.01%	1637
2024 Q2	$422K	Sell	3,091 -64,453	-95%	-$8.77M	﹤0.01%	1641
2024 Q1	$10.2M	Hold	67,544	–	–	0.02%	443
2023 Q4	$8.51M	Hold	67,544	–	–	0.02%	480
2023 Q3	$6.32M	Sell	67,544 -149	-0.2%	-$13.9K	0.01%	506
2023 Q2	$6.04M	Hold	67,693	–	–	0.01%	538
2023 Q1	$7.26M	Hold	67,693	–	–	0.02%	470
2022 Q4	$8.27M	Buy	67,693 +44,650	+194%	+$5.18M	0.02%	457
2022 Q3	$2.38M	Hold	23,043	–	–	0.01%	727
2022 Q2	$2.14M	Buy	23,043 +6,237	+37%	+$588K	0.01%	775
2022 Q1	$1.97M	Sell	16,806 -3,475	-17%	-$402K	﹤0.01%	897
2021 Q4	$2.73M	Buy	20,281 +2,596	+15%	+$386K	0.01%	851
2021 Q3	$2.82M	Sell	17,685 -11,000	-38%	-$1.51M	0.01%	919
2021 Q2	$3.77M	Sell	28,685 -38,197	-57%	-$5.09M	0.01%	774
2021 Q1	$8.62M	Buy	66,882 +28,537	+74%	+$4.34M	0.02%	458
2020 Q4	$6.39M	Sell	38,345 -12,695	-25%	-$2.1M	0.01%	530
2020 Q3	$7.88M	Buy	51,040 +5,371	+12%	+$772K	0.02%	492
2020 Q2	$6.75M	Buy	45,669 +2,711	+6%	+$372K	0.02%	520
2020 Q1	$4.84M	Sell	42,958 -6,356	-13%	-$826K	0.02%	519
2019 Q4	$6.86M	Buy	+49,314	New	+$5.48M	0.02%	549

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Ensign Peak Advisors's ASND Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Ascendis Pharma A/S (ASND) stake by 48% in Q2 2026, selling an estimated $1.51M and leaving 7,116 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #753.

Ensign Peak Advisors first reported a position in ASND in Q4 2019 and has held it in 27 quarters since. The position peaked at $14.8M in Q4 2025. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Ensign Peak Advisors held 7,116 shares of Ascendis Pharma A/S worth $1.9M as of Q2 2026.
Ensign Peak Advisors sold 6,446 Ascendis Pharma A/S shares in Q2 2026, an estimated $1.51M.
Ascendis Pharma A/S made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #753 holding.
Ensign Peak Advisors first reported a position in Ascendis Pharma A/S in Q4 2019 and has held it in 27 quarters since.
Ensign Peak Advisors's Ascendis Pharma A/S position peaked at $14.8M in Q4 2025.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.